Heat Biologics is a cutting-edge biopharmaceutical company that aims to develop innovative therapies to modulate the immune system. Its gp96 platform focuses on activating immune responses against cancer and pathogenic antigens. The company has several product candidates in the pipeline, including HS-110, which is in Phase 2 trial, HS-130 in Phase 1, and a COVID-19 vaccine program in preclinical development. Moreover, Heat is also working on a portfolio of immunomodulatory antibodies, with PTX-35 currently enrolling in a Phase 1 trial. With its unique approach to tackling immune-related diseases, Heat Biologics is poised to make significant strides in the pharmaceutical industry.
Heat Biologics, Inc.'s ticker is HTBX
The company's shares trade on the NASDAQ stock exchange
They are based in Durham, North Carolina
There are 11-50 employees working at Heat Biologics, Inc.
It is https://www.heatbio.com/
Heat Biologics, Inc. is in the Healthcare sector
Heat Biologics, Inc. is in the Biotechnology industry
The following five companies are Heat Biologics, Inc.'s industry peers: